Discontinuing osteoporosis pharmacotherapy in postmenopausal women – can they risk taking a break? Clinical Brief Series - Certificate of Completion
This is a 4-part Clinical Brief series that has been accredited with RACGP. Participants must read all 4 issues and then complete the questions on Issue 4 to claim CPD points.Please ensure that you have read all four parts of this Clinical Brief series, then complete the following 5 questions in order to claim your CPD points.
This interactive online learning activity is valued at 1 Hour(s) of continuing education.
MBBS, MWell, DipRACOG
South Coast Medical
Blairgowrie, Victoria, Australia
On completion of this program, participants will be better able to:
- Recall the different modes of action, onset of action and duration of action of osteoporosis pharmacotherapies
- Counsel patients on the safety and efficacy of long-term osteoporosis pharmacotherapy
- Evaluate the benefits and risks of long-term osteoporosis pharmacotherapy, including the risk of osteonecrosis of the jaw (ONJ) and atypical fracture of the femur (AFF)
- Implement strategies for discontinuation of osteoporosis pharmacotherapies in order to minimise the risk of rebound fracture